Dr. Vasileios C. Kyttaris, MD

Dr. Kyttaris practices at Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health.

Dr. Kyttaris' NPI, 1851344139, was assigned on May 18, 2006. Dr. Kyttaris holds District of Columbia license MD33326.

Dr. Kyttaris' primary practice is Beth Israel Deaconess Medical Center, at 330 Brookline Avenue, Boston, MA 02215 in Suffolk County. The practice phone is (617) 667-7000.

Dr. Kyttaris' primary practice is Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health. Dr. Kyttaris is also affiliated with Lahey Clinic. The medical group on file is Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center (HMFP). Dmand AI also links Dr. Kyttaris to 2 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kyttaris practices, 6 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Kyttaris' primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Kyttaris is licensed in District of Columbia.

CMS data shows 767 Medicare services from Dr. Kyttaris across 7 procedure codes in 2024, for 278 Medicare patients. Medicare paid $41,447 for them.

CMS counts 278 Medicare patients who saw Dr. Kyttaris in 2024. The largest group is 65 to 74, with 104 patients. 71% of them have arthritis, and 71% have high cholesterol. 26% are also on Medicaid. Their average risk score is 1.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kyttaris' median patient age at 65, with 65% women.

In 2024, Dr. Kyttaris wrote 1,301 Medicare Part D claims for 198 patients. 70% of them were for generic drugs. CMS names the drug for 1,157 of them, across 31 drugs with 11 or more claims each, at $2,081,810 in total drug cost. In 2023, CMS named 1,057 claims across 29 drugs.

Dr. Kyttaris accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kyttaris as offering telehealth.

Dmand AI links 80 papers to Dr. Kyttaris, published from 2007 to 2025. 2021 was the busiest year, with 7. The most frequent topics are Lupus Erythematosus, Systemic, T-Lymphocytes and Lymphocyte Activation. Dr. Kyttaris has published most often in Arthritis Rheumatol. Dr. Kyttaris' most frequent co-authors are George C. Tsokos, MD, Afroditi Boulougoura and Ratnesh Chopra, MD.

Dmand AI links Dr. Kyttaris to 4 clinical trials. Conditions studied include Lupus Erythematosus, Systemic and Connective Tissue Diseases. Open Payments lists research payments to Dr. Kyttaris that name 2 trials.

CMS Open Payments shows 61 general payments to Dr. Kyttaris from 14 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 81% of the total. AstraZeneca Pharmaceuticals LP paid the most, $17,396. It also lists 10 research payments totaling $15,644 from 2019 to 2021, naming 2 clinical trials.